NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









ImpriMed, Inc.

ImpriMed, Inc.

Private
Palo Alto, CaliforniaHealthcare & Life Scienceshttps://imprimedicine.com/

Last Round

Series A

Dec 19, 2023

Est. Valuation

$47.52M

Total Funding Raised

$27.03M

Momentum

Top 5%

of companies Caplight tracks

Company Overview

ImpriMed, Inc. is a precision medicine company that utilizes artificial intelligence and lab testing of live cancer cells to predict patient response to various cancer treatments.

Sector

Healthcare & Life Sciences

Verticals

Precision Medicine, Medical AI, Biotechnology, Healthcare Analytics

Business Model

B2B

Customer Profile

Usage-Based SaaS

AI Layer

Application

Keywords

veterinary oncologyprecision medicinedrug response predictionvet techAI diagnosticsclinical decision supportchemotherapy selectionveterinary AIdrug sensitivity assaypet cancer treatmentmedical AIusage-based billingbiotechnologyhealthcare analytics

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

ImpriMed, Inc. Comparables

Compare ImpriMed, Inc. with similar companies based on industry and business-model similarity.

ImpriMed, Inc. comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
FidoCure
85%
Anivive Lifesciences
77%
VetOmics
74%

ImpriMed, Inc. Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series ADec 19, 2023
VC RoundApr 13, 2021
SeedApr 12, 2019
Pre SeedJun 1, 2018

Key People

Founding team and executive leadership

Minh B.

Sr. Customer Success EA To The CEO, Biz Ops

Executive Team

Sungwon Lim

CEO, Co-Founder

Founding Team

Mario Castellon

Interim Chief Financial Officer

Executive Team

ImpriMed, Inc. Investors

Notable investors and investment history

ImpriMed, Inc. investors
InvestorRounds
Draper DragonVC Round
StartXSeed
Plug and Play Tech CenterSeed, Pre Seed
Han River PartnersSeries A
Murex PartnersVC Round, Series A, Seed
BonAngels Venture PartnersVC Round
ES InvestorVC Round

Market signals

Structured signals derived from secondary market and firmographic data.

  • Mar 4, 2026

    Helped over 11,000 dogs and cats with cancer.

  • Mar 4, 2026

    Reached 288 specialty hospital customers in the US.

ImpriMed, Inc. Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

ImpriMed, Inc. Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about ImpriMed, Inc.'s valuation, stock price, and market status.

Firmographic Details

HeadquartersPalo Alto, California
Employee Range47
Year Founded2017
Last FundingDec 19, 2023

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.